<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">DA0B8</CoID>
		<CoID Type="CompanyName">Oxford Pharmascience Group Plc</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">OXP</IssueID>
			<IssueID Type="CUSIP">G6855K101</IssueID>
			<IssueID Type="ISIN">GB00B3LXPB43</IssueID>
			<IssueID Type="RIC">OXP.L</IssueID>
			<IssueID Type="SEDOL">B3LXPB4</IssueID>
			<IssueID Type="DisplayRIC">OXP.L</IssueID>
			<IssueID Type="InstrumentPI">67577772</IssueID>
			<IssueID Type="QuotePI">68300243</IssueID>
			<Exchange Code="SEA" Country="GBR">SEATS (AIM Market)</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2016-01-29</LastModified>
		<LatestAvailableAnnual>2014-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2014-12-31">11</Employees>
		<SharesOut Date="2015-06-30" TotalFloat="753047285.0">1205661619.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">0.70681</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-08-20T07:31:04">Oxford Pharmascience Group plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in re-developing medicines. The Company primarily engages in research and development activities based around its core technology platforms. The Company seeks to commercialize the related products to pharmaceutical organizations. The Company's pipeline is focused on pain relief and cardiovascular disease indications addressing unmet patient needs in global markets. Its pipeline includes Ibuprofen, Naproxen, Diclofenac and Aspirin. Its nonsteroidal anti-inflammatory drug (NSAID) clinical development program involves re-developing NSAIDs to make them milder in the gastrointestinal (GI) tract and mask the typical NSAID taste/burn. The Company's SafeStat clinical development program includes developing statins platform. The Company's OXPzero Technology releases the drug in its molecular ionized form, reducing localized concentration.</Text>
		<Text Type="Financial Summary" lastModified="2016-01-29T01:31:19">BRIEF: For the six months ended 30 June 2015, Oxford Pharmascience Group Plc revenues increased 2% to L342K. Net loss increased 25% to L2.2M. Revenues reflect Brazil segment increase of 5% to L317K. Higher net loss reflects Administrative expenses increase of 22% to L2.3M (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2016-01-29T01:31:20">
		<streetAddress line="1">2 Royal College Street Camden</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>LONDON</city>
		<state-region></state-region>
		<postalCode>NW1 0NH</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>20</city-areacode>
				<number>75545875</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2013-06-05T00:00:49"><webSite mainCategory="Home Page">http://www.oxfordpharmascience.com</webSite><eMail mainCategory="Company Contact/E-mail"></eMail></webLinks>
	<peerInfo lastUpdated="2016-01-29T01:31:20">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201010" mnem="">Biotechnology &amp; Medical Research - NEC</Industry>
			<Industry type="NAICS" order="1" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="NAICS" order="2" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="NAICS" order="3" reported="0" code="325411" mnem="">Medicinal and Botanical Manufacturing</Industry>
			<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
			<Industry type="SIC" order="2" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="3" reported="0" code="2833" mnem="">Medicinals And Botanicals</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="03/01/2011">
			<firstName>Marcelo</firstName>
			<mI>Leonardo</mI>
			<lastName>Bravo</lastName>
			<age></age>
			<title startYear="2014" startMonth="03" startDay="05" iD1="CEO" abbr1="CEO" iD2="EDR" abbr2="Exec. Dir.">Chief Executive Officer, Executive Director</title>
		</officer>
		<officer rank="2" since="NA">
			<firstName>Christopher</firstName>
			<mI></mI>
			<lastName>Hill</lastName>
			<age></age>
			<title startYear="2013" startMonth="10" startDay="17" iD1="CFO" abbr1="CFO" iD2="EDR" abbr2="Exec. Dir.">Chief Financial Officer, Executive Director, Company Secretary</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2014-12-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">0.04625</Ratio>
			<Ratio FieldName="NHIG" Type="N">0.95500</Ratio>
			<Ratio FieldName="NLOW" Type="N">0.04000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">0.07762</Ratio>
			<Ratio FieldName="EV" Type="N">49.05585</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">55.76185</Ratio>
			<Ratio FieldName="AREV" Type="N">0.70500</Ratio>
			<Ratio FieldName="AEBITD" Type="N">-3.48600</Ratio>
			<Ratio FieldName="ANIAC" Type="N">-2.86400</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">-0.00285</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.00070</Ratio>
			<Ratio FieldName="ABVPS" Type="N">0.00728</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.00667</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">-0.00284</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">31.63121</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">-33.26365</Ratio>
			<Ratio FieldName="APR2REV" Type="N">79.09482</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">6.35408</Ratio>
			<Ratio FieldName="Employees" Type="N">11</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2015" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2015" CurInterimEndMonth="9" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-11.56250</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">0.80000</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-0.00400</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-4.50000</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
